Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06488417 · ClinicalTrials.gov registry record · NA
Frankincense Supplements and Inflammation
A NA study, sponsored by dōTERRA International.
- Completed
- Registry status
- NA
- Development phase
- 67
- Enrollment target
NCT06488417: Completed NA study, sponsored by dōTERRA International.
NCT06488417 is a NA study that has completed, run by dōTERRA International. The registered enrollment target is 67 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06488417, a NA study, has completed, sponsored by dōTERRA International.
- COMPLETED
- Registry status
- NA
- Development phase
- 67 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn whether frankincense essential oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are: 1. Do frankincense essential oil supplements affect gene expression and protein markers as measured in blood? 2. How does daily ingestion of frankincense supplements affect anthropometric measurements, including body mass index, waist circumference, blood pressure, and heart rate? 3. How does daily ingestion of frankincense essential oil supplements affect subjective quality of life and health parameters? 4. Is ingesting frankincense essential oil supplements daily safe, as measured by laboratory tests and adverse events? Researchers will compare two types of frankincense essential oil supplements. One type contains frankincense essential oil and boswellic acid as its active ingredients. The other type contains only frankincense essential oil as its active ingredient. Participants will: * Be assigned one of the two types of frankincense essential oil supplement * Take two capsules of their assigned supplement every day for about 30 days * Attend two study visits in which they provide blood and urine samples, complete subjective health and quality of life assessments, and undergo anthropometric measurements * Complete weekly subjective health assessments from home
Primary Outcome
Gene expression analysis refers to a genome-wide quantification of methylation. EPIC850k array will be used for methylation analysis. This represents approximately 900,000 gene locations. The main feature performed is a differential methylation analysis to determine what has significantly changed from one time point to another.
Interventions
- DIETARY_SUPPLEMENT Frankincense essential oil + boswellic acid supplement
- DIETARY_SUPPLEMENT Frankincense essential oil supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2024-06-17 |
| Est. Completion | 2024-08-21 |
| Phase | NA |
What the finished NCT06488417 record still lists
NCT06488417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 67 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Frankincense essential oil + boswellic acid supplement is the first listed.
NCT06488417 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06488417 about?
NCT06488417 is a clinical study titled "Frankincense Supplements and Inflammation". The goal of this clinical trial is to learn whether frankincense essential oil-based supplements can affect gene expression and serum protein markers in healthy volunteers. The main questions it aims to answer are: 1. Do frankincense essential oil supplements affect gene expression and protein mark...
What is the current status of trial NCT06488417?
This trial is currently completed. It is a NA study. The enrollment target is 67 participants. The study started on 2024-06-17. Estimated completion is 2024-08-21.
What interventions are being tested in trial NCT06488417?
The interventions under investigation include: Frankincense essential oil + boswellic acid supplement (DIETARY_SUPPLEMENT), Frankincense essential oil supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06488417?
This trial is sponsored by dōTERRA International, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06488417's enrollment target sits among peer trials
67 1139th of 2000 higher than 862 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03213002 · 67 participants · Phase 1
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
- NCT04115163 · 67 participants · Phase 2
Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
- NCT04315324 · 67 participants · Phase 1
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
- NCT04532424 · 67 participants · NA
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI